Status of immunotherapy for advanced lung cancer in 10 cities of 2 provinces in southwest China
Objective To analyze the distribution of immunotherapy for advanced lung cancer in 10 cities in southwest China and to provide reference for the prevention and treatment of advanced lung cancer.Methods The data of patients with ad-vanced lung cancer treated with immunotherapy from 2018-01-01 to 2022-05-31 in 19 hospitals in 10 prefectures of 2 prov-inces in Southwest China were collected.Excel 2019 and SPSS 29.0 software were used to process the data.Descriptive statistics was used to analyze the baseline characteristics and the occurrence of adverse drug reactions by stratification.Results A total of 1 043 patients with advanced lung cancer were collected in this study,mainly distributed in hospitals of 10 cities,such as Zunyi,Suining and Liupanshui et al.The age of all included patients ranged from 23 to 94 years,with a median age of 61 years.Among them,801 cases(76.80％)were male,609 cases(58.38％)had a history of smok-ing,631 cases(60.50％)lived in urban areas,and 436 cases(41.80％)were employees of enterprises and public institu-tions.There were 413 cases(39.59％)of lung squamous cell carcinoma,449 cases(43.04％)of lung adenocarcinoma,132 cases(12.67％)of small cell lung cancer,49 cases(4.70％)of other pathological types,900 cases(86.29％)of stageⅣ patients.There were 1 015 patients(97.41％)with ECOG score 0-2 and 176 patients(16.87％)with positive driver gene.The detection rate of programmed death protein ligand-1(PD-L1)was 17.16％,the utilization rate of programmed death protein 1(PD-L1)inhibitor was 95.78％,the first-line utilization rate of PD-1/PD-L1 inhibitor was 55.99％,and the combined treatment rate of PD-1/PD-L1 inhibitor accounted for 80.54％.The utilization rate of domestic PD-1/PD-L1 inhibitors was 90.13％,and 876 cases(83.98％)were used for indications.The overall incidence of immune-relat-ed adverse reactions was 68.26％,among which grade 3 to 5 accounted for 13.23％.Ninety-five patients(9.10％)were discontinued due to adverse reactions,4 died due to severe immune-related pneumonia,and 1 died due to immune-related myocarditis.The vast majority of immune-related adverse reactions improved after brief discontinuation or symptomatic hormonal therapy.Conclusions Immunotherapy for advanced lung cancer in some areas of southwest China has some problems,such as limited coverage of patients,limited access to drugs and relatively insufficient drug use experience in some hospitals,which need to be further improved.
Southwest Chinaadvanced lung cancerimmunotherapythe status quosurvey
NETL
NSTL
万方数据
